NCT05983783View on ClinicalTrials.gov

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

PHASE3RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Metastatic Prostate CancerHormone Sensitive Prostate CancerChemotherapy Effect
Interventions
DRUG

Docetaxel

This is Triple drug regimen for mHSPC

DRUG

Rezvilutamide

This is doubling drug regimen for mHSPC

Trial Locations (1)

210029

RECRUITING

Urology dpt, First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER